This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.1 | Synonyms: Glanzmann thrombasthenia, GT, Thrombasthenia, GP IIb/IIIa deficiency
In 1918, the Swiss pediatrician Eduard Glanzmann first described as an independent disease patients who had a severe bleeding tendency with a normal platelet count and normal platelet morphology but markedly impaired platelet function. At the time, the name thrombasthenia was given in the sense that the platelets were 'weak (asthenic)'.
As research on platelet surface glycoproteins advanced in the 1970s, in 1974–1975 Nurden and Caen first demonstrated that the cause was deficiency or dysfunction of GP IIb (glycoprotein IIb) and GP IIIa in the platelets of patients with Glanzmann's thrombasthenia. Subsequently, GP IIb (ITGA2B gene) and GP IIIa (ITGB3 gene) were shown to be essential for platelet aggregation as the fibrinogen receptor.
In the 1980s–90s, the GP IIb/IIIa complex was confirmed to be αIIbβ3 integrin. When activated, this receptor recognizes the RGD sequence of fibrinogen, vWF, fibronectin, vitronectin and others, forming bridges between platelets. This discovery led to the development of antiplatelet drugs (GP IIb/IIIa inhibitors such as abciximab, eptifibatide and tirofiban).
The cause of Glanzmann's thrombasthenia is mutations in the ITGA2B (17q21.31, encoding αIIb/GP IIb) or ITGB3 (17q21.32, encoding β3/GP IIIa) gene. Various mutations have been reported, including gene deletions, missense variants, nonsense variants, splicing variants and frameshift variants.
| Type | GP IIb/IIIa expression | Intraplatelet fibrinogen | Severity |
|---|---|---|---|
| Type I | Less than 5% of normal | Deficient | Most severe |
| Type II | 10–20% of normal | Reduced but present | Moderate |
| Variant | Normal or above | Normal | Dysfunctional |
Glanzmann's thrombasthenia is inherited in an autosomal recessive manner. It is caused by homozygous or compound heterozygous variants. Heterozygous carriers usually have no clinical symptoms, and a mild reduction in platelet GP IIb/IIIa expression may be observed in some.
Founder mutations have been reported in specific ethnic groups: an ITGA2B exon 12 mutation (Cys598Tyr) in Iraqi Jews, an ITGB3 variant in French Gypsies, and a specific ITGA2B variant in Arab Palestinians. In these groups, the frequency of homozygosity due to consanguineous marriage is high.
More than 300 pathogenic variants have been reported to date. ITGA2B variants are reported more frequently than ITGB3 variants, and missense variants in domains essential for αIIbβ3 complex formation are the most common.
Glanzmann's thrombasthenia is a very rare disease, with a worldwide prevalence estimated at less than 1 per million. However, incidence is higher in populations where consanguineous marriage is common (Iranian Jews, Arabs, populations of southern India, Gypsies, etc.).
According to the international Glanzmann thrombasthenia registry (GT-Registry, Europe), the most common bleeding symptoms are epistaxis (96%), gum bleeding (62%), skin bleeding (52%) and menorrhagia (more than 90% of female patients).
In Korea, Glanzmann's thrombasthenia is extremely rare, and reported cases are very few. A small number of cases have been identified through the national rare disease registry and case reports of the Korean Society of Hematology. Glanzmann's thrombasthenia should be included in the differential diagnosis in cases of unexplained bleeding tendency with a normal platelet count, especially with complete absence of platelet aggregation.
αIIbβ3 (GP IIb/IIIa) is the most abundant integrin on platelets, expressed at about 80,000 copies per platelet. In the inactive state, it has low affinity for fibrinogen, but after platelet activation (ADP, thrombin, collagen stimulation), it switches to a high-affinity state through a conformational change (inside-out signaling). Activated αIIbβ3 recognizes and binds the RGD sequence of fibrinogen, vWF and fibronectin, which serve as bridges for platelet aggregation.
When αIIbβ3 is deficient or dysfunctional: ① platelet aggregation is impossible because bridges between platelets cannot form via fibrinogen and vWF, ② fibrinogen storage in platelet alpha granules is reduced (type I), ③ clot retraction does not occur (useful for diagnosis). Therefore, platelet aggregation by all physiological agonists is completely blocked.
Because GP Ib-IX-V (the vWF receptor) is normal, platelet aggregation/agglutination by ristocetin is normal. This is the key distinguishing point from BSS.
In almost all patients, bleeding symptoms appear from early life. Epistaxis and gum bleeding are the most common and recurrent. Menorrhagia is a serious problem in female patients and can lead to anemia. Skin petechiae, purpura and ecchymoses occur. Excessive and prolonged bleeding with surgery, tooth extraction and trauma is characteristic.
Severe bleeding (intracranial hemorrhage, gastrointestinal bleeding, hemarthrosis, intra-abdominal bleeding) is rare but a life-threatening complication. It sometimes presents as intracranial hemorrhage in the neonatal period. Life-threatening bleeding is reported to be experienced by about 4–5% of all patients.
One of the characteristic findings of Glanzmann's thrombasthenia is a normal platelet count. This is also a reason the diagnosis is missed in clinical practice.
Skin petechiae, purpura, ecchymoses. Pallor due to anemia (with repeated bleeding). Traces of bleeding in the nasal cavity. Because the platelet count is normal, there are no findings related to thrombocytopenia, such as splenomegaly.
Complete blood count (CBC): normal platelet count, normal platelet size. PFA-100: markedly prolonged collagen/ADP and collagen/epinephrine closure times. Platelet aggregation testing (light transmission aggregometry): complete absence of aggregation in response to ADP, collagen, epinephrine and arachidonic acid is diagnostic. Aggregation by ristocetin is normal (GP Ib normal). Clot retraction test: no retraction or markedly reduced. Flow cytometry: markedly reduced expression of CD41 (GP IIb/αIIb) and CD61 (GP IIIa/β3).
Suspect Glanzmann's thrombasthenia in the following cases: ① severe mucosal bleeding despite a normal platelet count, ② complete absence of aggregation to various agonists on platelet aggregation testing, ③ only ristocetin aggregation normal, ④ no clot retraction, ⑤ bleeding tendency from childhood + normal PT/aPTT.
CBC + blood smear (confirming normal platelet count and size). PT, aPTT (normal). PFA-100 (prolonged closure time). Platelet aggregation testing (including ADP, collagen, ristocetin).
If abnormalities are found on initial screening, flow cytometry (quantification of CD41 and CD61 expression) and molecular genetic testing are performed at a specialized laboratory.
Flow cytometry quantifies CD41 (αIIb) and CD61 (β3) expression on the platelet surface, and if expression is less than 5–20% of normal controls, type I or type II Glanzmann's thrombasthenia is diagnosed. In the variant form, expression levels are normal but fibrinogen binding after activation is reduced.
Pathogenic variants are identified by direct sequencing of the ITGA2B and ITGB3 genes or by an NGS panel. Variant identification is essential for treatment planning (when HSCT is considered) and family genetic counseling.
Bernard-Soulier syndrome: giant platelets + thrombocytopenia + absent ristocetin aggregation (ristocetin aggregation is normal in Glanzmann's thrombasthenia). Platelet granule deficiency: reduced ADP/collagen aggregation but not complete absence. Aspirin use: selective inhibition of only the thromboxane A2 pathway, partial reduction of ADP aggregation.
Antifibrinolytics (tranexamic acid): used for mucosal bleeding, perioperatively and before tooth extraction. DDAVP: limited efficacy in Glanzmann's thrombasthenia but tried in some mild cases. Oral contraceptives or intrauterine device (levonorgestrel IUD): control of menorrhagia.
Platelet transfusion is required for severe bleeding, surgery and delivery. A major problem with repeated transfusion is the development of transfusion refractoriness due to formation of alloantibodies (anti-αIIb or anti-β3 antibodies). In patients refractory to transfusion, HLA-matched, leukoreduced platelets are recommended.
rFVIIa (NovoSeven 90 μg/kg, repeated as needed) is effective for bleeding in Glanzmann's thrombasthenia refractory to platelet transfusion. In Europe, use of rFVIIa in Glanzmann's thrombasthenia is officially approved.
Allogeneic HSCT is considered in patients, especially children, with recurrent severe bleeding refractory to platelet transfusion. Successful HSCT brings complete recovery of platelet function. Careful patient selection is required, considering transplant-related mortality (5–15%), graft-versus-host disease and the risk of graft failure.
Research on lentiviral vector- and CRISPR/Cas9-based gene correction aimed at re-expressing the αIIbβ3 genes is under way at the preclinical stage.
Most patients with Glanzmann's thrombasthenia can survive into adulthood with appropriate management. Bleeding-related death (especially intracranial hemorrhage) is rare but can occur. Iron overload and alloimmunization due to repeated transfusion are long-term complications. In patients who develop transfusion refractoriness due to alloantibody formation, management of severe bleeding becomes difficult.
The risk of bleeding is high with menorrhagia, pregnancy and delivery. It is managed with iron supplementation, oral contraceptives and planned delivery (with prophylactic rFVIIa or platelet transfusion prepared).
After successful HSCT, platelet function normalizes and the bleeding tendency disappears. In international registry data, 5-year survival after HSCT is about 85–90% or higher.
Antiplatelet drugs (aspirin, NSAIDs, P2Y12 inhibitors) are prohibited. GP IIb/IIIa inhibitors (abciximab, eptifibatide, etc.) are absolutely prohibited. Trauma and contact sports are restricted.
Before any invasive procedure, consultation with a hematologist and preparation of platelet transfusion or rFVIIa. The presence of alloantibodies is checked in advance to plan the transfusion strategy.
Patients and families are informed about the autosomal recessive mode of inheritance, recurrence risk, carrier testing, and the possibility of prenatal genetic testing by CVS or amniocentesis.